

# Stability Indicating Method for the Determination of Related Substances in Felodipine Solid Dosage Form and in the Drug Substance by RP-HPLC

Manoj Kumar Vadlamudi<sup>1,2</sup> and Sangeetha Dhanaraj<sup>1\*</sup>

<sup>1</sup>School of Advanced Sciences, VIT University, Vellore-632014, Tamil Nadu, India

<sup>2</sup>Analytical Research and Development, Ashland (India) Private Limited, Hyderabad-500078, Telangana, India

## Abstract

**Background:** Methods were not available in the monographs like United States Pharmacopeia, British pharmacopeia and European pharmacopeia and also in the literature for the determination of three related impurities namely Impurity A, B and C in Felodipine solid dosage form with a shorter runtime using RP-HPLC.

**Method:** A simple RP- HPLC method was developed and validated for the quantification of Felodipine Impurity A, B and C in Felodipine solid dosage form and in drug substance. This method was developed on waters alliance using Phenomenex Gemini column C<sub>18</sub> 5  $\mu$ m, 150  $\times$  2.0 mm i.d, using the isocratic program with the mobile phase ratio of 0.02 mM ammonium acetate adjusted to pH 5 and acetonitrile (55:45, v/v) with a flow rate of 0.7 mL/min. The  $\lambda_{\text{max}}$  is at 240 nm.

**Results:** Forced degradation was performed as per ICH guidelines and no interference of the impurities with the known peaks was found. Precision was found between 0.1 and 0.2%. The Limit of detection and quantification for Felodipine and impurity A; Impurity B and C were 0.05 and 0.15  $\mu$ g/mL respectively. The linearity correlation coefficient was found to be >0.999 for Impurity A and Felodipine; Impurity B and C of concentration range 0.2-30.0  $\mu$ g/mL and 0.2-8.0  $\mu$ g/mL respectively. The method accuracy was assessed for Felodipine and its impurities at four levels (LOQ, 50%, 100% and 150%) and the recovery ranged from 95% to 106%.

**Conclusion:** The method was found to be precise, reliable, accurate and robust.

**Keywords:** Felodipine; Impurity A; Impurity B; Impurity C; Forced degradation; Validation; RP-HPLC

## Introduction

Hypertension is an important risk factor for atherosclerosis and the beneficial effects of lowering blood pressure on the vascular morbidity and mortality is well documented and demonstrated. Felodipine (FD) is chemically referred to as 3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic is an anti-hypertensive drug with molecular formula C<sub>18</sub>H<sub>19</sub>Cl<sub>2</sub>NO<sub>4</sub> and molecular weight 384.254 g/mol (Table 1) [1,2]. FD decreases arterial smooth muscle contractility and subsequent vasoconstriction by inhibiting the influx of calcium ions through voltage-gated L-type calcium channels. FD may be used to treat mild to moderate essential hypertension [3] FD, a new generation calcium channel antagonist, belonging to the class of dihydropyridines, is a practical advance in the treatment of hypertension [4,5]. FD is a highly vasodilative calcium antagonist that effectively reduces arterial blood pressure [6].

There were no methods listed in the USP, EP and BP monographs as well as in the literature for the determination of three impurities namely Impurity A (Imp A), Impurity B (Imp B) and Impurity C (Imp C) in FD solid dosage form with shorter runtime. USP and BP monographs lists the determination of Imp-A only and The EP monograph list the determination of three impurities (Imp A, B and C) but, only for bulk drug and not for the formulation and also the runtime was about 30 min.

The goal of the study was to provide a stability indicating method for the quantification of three related substances (Imp A, B and C) in drug substance and in solid dosage form with shorter runtime.

## Experimental

### Chemicals and reagents

Acetonitrile (HPLC grade), disodium hydrogen orthophosphate,

acetic acid and ammonium acetate were obtained from Merck Chemicals. Standard FD, Imp A, B and C were obtained from Ashland India Private Limited, Hyderabad, Telangana, India. All the other chemicals were of analytical grade and Milli-Q water was used.

### Instrument

HPLC alliance Waters e2695 with photodiode array detector.

### Chromatographic conditions

The Chromatography was performed by using a mobile phase having a fixed combination of 0.02 mM ammonium acetate (adjusted to pH 5 with glacial acetic acid) and acetonitrile (55:45, v/v) with a flow rate of 0.7 mL/min was used and equipped with Phenomenex Gemini column C<sub>18</sub> 5  $\mu$ m, 150  $\times$  2.0 mm i.d. The wavelength maximum was at 240 nm and the column temperature used was 25°C and the total run time was 15 min.

### Sample preparation

Twenty tablets were weighed and finely powdered, and amount of powder equivalent to 50 mg FD was accurately weighed and transferred

**\*Corresponding author:** Sangeetha Dhanaraj, School of Advanced Sciences, VIT University, Vellore-632014, Tamil Nadu, India, Tel: 914162243091/93; E-mail: [dsangeetha@vit.ac.in](mailto:dsangeetha@vit.ac.in)

**Received** March 29, 2016; **Accepted** May 01, 2016; **Published** May 08, 2016

**Citation:** Vadlamudi MK, Dhanaraj S (2016) Stability Indicating Method for the Determination of Related Substances in Felodipine Solid Dosage Form and in the Drug Substance by RP-HPLC. J Bioequiv Availab 8: 153-166. doi:[10.4172/jbb.1000287](https://doi.org/10.4172/jbb.1000287)

**Copyright:** © 2016 Vadlamudi MK, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

to a 50 mL volumetric flask and about 30 mL of acetonitrile was added and sonicated for 15 minutes, the solution was made up to the mark using acetonitrile. The solution was centrifuged at 4500 rpm for 10 minutes and the clear supernatant was filtered through a 0.45 µm membrane filter and injected onto the HPLC system.

## Method development and optimization of chromatographic conditions

Concentration of FD, Imp A, B and C used are as shown in the Table 2.

**Trial-1:** Since the pKa of FD is 5.4, hence pH of 0.02 mM disodium hydrogen phosphate as mobile phase A was adjusted to pH 5 using 10%

v/v, orthophosphoric acid) and acetonitrile as mobile phase B equipped with column X-Bridge C18 having dimensions 33 mm × 3.5 mm i.d., 5 µm particle size, flow rate of 1.0 mL/min. The wavelength maximum found at 240 nm.

**Trial-2:** Continued to trial-1, here X-Terra C<sub>18</sub> column having dimensions 20 mm × 3.5 mm i.d., 4.6 µm particle size with the same mobile phase A and B as in trial-1 was used but, here the ratios were altered to get better resolution in a shorter run time.

**Trial-3:** From trial-1 and 2 shows it was difficult to get the separation in a shorter runtime with good resolution. So phenomenex Gemini C<sub>18</sub> column having dimensions 150 mm × 2.0 mm i.d., 5 µm particle size with 5.0 pH 0.02 mM ammonium acetate (adjusted pH with glacial acetic acid) as mobile phase A and acetonitrile as mobile phase B was used, different ratios were altered to reach the better separation in a shorter runtime.

**Forced degradation study:** In order to demonstrate the method is stability indicating, forced degradation study was performed in different conditions as per ICH guidelines, hydraulic (acid, base and neutral), oxidation, thermal, sunlight, humidity and photolytic conditions.

**Hydraulic condition:** It is a chemical process that includes decomposition of a chemical compound by reaction with acid, base and water. Stress study was performed by refluxing tablet powder equivalent to 1 mg/mL of FD with 2 N hydrochloric acid, 2 N sodium hydroxide and water at 60°C for 5 h [7,8].

**Oxidative condition:** Oxidative study was performed by refluxing equivalent tablet powder 1 mg/mL of FD in 3% of hydrogen peroxide at 60°C for 5 h [7].

**Photolytic conditions:** Photolytic testing of drug substances and products was essential to demonstrate that light exposure does not affect the same. These studies were evaluated with 1 mg/mL of FD tablet powder by exposure to fluorescent conditions about 1.2 million lx h and 200 W h/m<sup>2</sup> light [7].





**Sunlight condition:** The sunlight testing of drug substances and products was essential to demonstrate that sunlight exposure does not affect on the same. The study was evaluated with 1 mg/mL of FD equivalent tablet powder by exposure to direct sunlight for 1 week [7].

**Thermal conditions:** A Thermal degradation study was carried with 1 mg/mL of FD equivalent tablet powder in a dry heat at higher temperatures (105°C) for a time period of 72 h.

**Analytical method validation:** Analytical method validation procedure to demonstrate that it is appropriate for its intended purpose [8].

### Parameters: Specificity

- Detection and Quantitation Limit
- Linearity
- Precision
- Repeatability
- Intermediate Precision
- Reproducibility
- Accuracy
- Range
- Robustness
- System suitability determination
- Solution stability studies

 <p><b>FD:</b> 3,5-Pyridinedicarboxylic acid 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester, (±)</p>
 <p><b>Imp A:</b> (ethyl methyl 4-(2,3-dichlorophenyl)-2,6-dimethylpyridine-3,5-dicarboxylate)</p>
 <p><b>Imp B:</b> 4-(2,3-Dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic Acid 3,5-Dimethyl Ester;</p>
 <p><b>Imp C:</b> 4-(2,3-Dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic Acid 3,5-Diethyl Ester;</p>

**Table 1:** Chemical names and structures of FD, Imp A, B and C.

Compound	Concentration	
	mg/mL	µg/mL
FD	1.0	1000
Imp A	0.02	20
Imp B	0.005	5
Imp C	0.005	5

**Table 2:** Concentration of FD and its impurities.

**Specificity:** Specificity is the ability to assess unequivocally the analyte in the presence of components which might include impurities, degradants and matrix [9].

**Detection and quantification limit:** The detection limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be detected, but need not to be necessarily quantitative as an exact value. The quantitation limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be quantitatively determined with suitable precision and accuracy [6].

**Linearity:** The Linearity of a method is its ability to obtain test results that are directly proportional to the sample concentration over a given range of concentration [9].

**Precision:** The precision is considered at three levels of repeatability, intermediate precision and reproducibility should be established using the homogeneous sample. The precision of an analytical procedure is expressed as the variance, standard deviation or coefficient of variation [9].

**Accuracy:** The accuracy of an analytical procedure is the closeness of the test results obtained by that procedure to the true value [9].

**Range:** The range of an analytical procedure is the interval between the upper and lower concentration (amounts) of analyte in the sample (including these concentrations) for which it has been demonstrated that the analytical procedure has a suitable level of precision, accuracy and linearity [6].

**Robustness:** The robustness is not a required validation element as per USP General Chapter <1225> but is described in this chapter. This analysis is therefore an optional validation element. The robustness of an analytical procedure are a measure of its capacity to remain unaffected by small, but deliberate variations in method parameters and are an indication of its reliability during normal usage [8].

**System suitability determination:** System suitability tests were performed to ensure that the HPLC system and analytical procedure are capable of providing deliberate and consistent results.

**Solution stability:** The each impurity at specified concentrations

with respect to the sample concentration were analyzed at different intervals of 1, 2 and 3 days at room temperature (25°C) and in refrigerator (5°C) conditions in order to know the stability of the sample solution as well as mobile phase stability at room temperature.

## Results and Discussion

### Development and optimization of chromatographic conditions

Method development and optimized from trial 1 to 3.

**Trial-1:** Here, for case 1, 2 and 3 unknown and Imp B peaks were found to be merging. In case 4 the peaks were well separated but the run time was about 60 min to elute all the impurities and also broadened peaks were observed. Details of the resolution are in Table 3 and respective chromatograms are shown in Figures 1-4.

**Trial-2:** Here, the peaks were merging in both the case 1 and 2. An unknown peak eluted at retention time of 2.399 min in case 2 was merged with Imp B. Details of the resolution are in Table 4 and respective chromatograms are shown in Figures 5 and 6.

**Trial-3:** Here, better separation was obtained in case 3 and 5, but in case 5 shorter run time as well as good resolution and theoretical plates were obtained. Details of the resolution are in Tables 5 and 6 and respective chromatograms are shown in Figures 7-11.


The developed method was found to be more economical using the set parameters.

### Forced degradation study


FD was observed degradable in thermal condition only. The purity angle was less than the threshold and also no purity flag was observed in all the conditions. The mass balance is more than 99.5%, hence the method was found to be stability indicating to get rid of all the degradants from the known and unknown impurities. The results are tabulated in Table 7 and respective chromatograms are shown in Figures 12-19.

Case#	%A	%B	Flow rate mg/mL	Resolution between Imp B and Imp A	Resolution between FD and Imp A	Resolution between FD and Imp C
Case 1	50	50	1.0	1.2	3.4	3.7
Case 2	55	45	1.0	3.0	1.9	4.1
Case 3	60	40	1.0	3.3	2.4	5.2
Case 4	65	35	1.0	2.7	2.7	5.0


**Table 3:** Detailed conditions for trial-1.




**Figure 1:** Chromatogram represents case 1 from trial 1.



**Figure 2:** Chromatogram represents case 2 from trial 1.



**Figure 3:** Chromatogram represents case 3 from trial 1.



**Figure 4:** Chromatogram represents case 4 from trial 1.

Case#	%A	%B	Flow rate mg/mL	Resolution between Imp B and Imp A	Resolution between FD and Imp A	Resolution between FD and Imp C
Case 1	60	40	1	1.1	3.7	3.8
Case 2	65	35	1	1.2	4.4	4.5

**Table 4:** Detailed conditions for trial-2.




Figure 5: Chromatogram represents case 1 from trial 2.




Figure 6: Chromatogram represents case 2 from trial 2.

Case#	%A	%B	Flow rate mg/mL	Resolution between Imp B and Imp A	Resolution between FD and Imp A	Resolution between FD and Imp C
Case 1	50	50	0.5	3.5	2.1	6.0
Case 2	55	45	0.5	3.9	2.9	7.2
Case 3	60	40	0.5	4.6	4.1	8.7
Case 4	53	47	0.5	3.6	2.5	6.5
Case 5	55	45	0.7	3.5	2.6	6.5

Table 5: Detailed conditions for trial-3.

Case#	%A	%B	Flow rate mg/mL	Theoretical plates			
				FD	Imp A	Imp B	Imp C
Case 1	50	50	0.5	4651	5176	4664	5743
Case 2	55	45	0.5	5347	6261	5318	6489
Case 3	60	40	0.5	5776	7563	5802	6796
Case 4	53	47	0.5	4863	5533	4775	5736
Case 5	55	45	0.7	4606	5319	4478	5181

Table 6: Detailed conditions for trial-3.


Analytical method validation

**System suitability solution:** The system suitability solution was prepared by taking 1.0 mg/mL of FD standard, 0.02 mg/mL of Imp A and 0.005 mg/mL of Imp C in acetonitrile. System suitability


parameters are mentioned in Table 8 and respective chromatogram as shown Figure 20.

**Relative response factor determination:** The relative response factors (RRF) were determined for the concentrations ranging from







**Figure 7:** Chromatogram represents case 1 from trial 3.




**Figure 8:** Chromatogram represents case 2 from trial 3.



**Figure 9:** Chromatogram represents case 3 from trial 3.



**Figure 10:** Chromatogram represents case 4 from trial 3.



**Figure 11:** Chromatogram represents case 5 from trial 3.


Condition	% Net Degradation	Purity Angle	Purity Threshold	Purity Flag
Unstressed	0.39	0.214	4.512	No
Acid stressed	1.25	0.247	3.621	No
Water	1.07	0.247	3.621	No
Base stressed	0.58	0.403	4.690	No
Peroxide stressed	0.5	0.083	6.187	No
Photolytic stressed	0.44	0.334	4.907	No
Sunlight stressed	0.42	0.300	4.845	No
Thermal stressed	5.21	0.275	5.052	No
Humidity	0.39	0.289	3.416	No

**Table 7:** Results of degradation studies.


10 to 150% of specification level of each impurity with respect to the sample concentration and also FD sample as unknown. The RRF of each impurity was determined by dividing the slope of each impurity by the slope of the sample from linearity curve and the results obtained is as shown in Table 9.

**Specificity:** The specificity was performed for forced degradation study and no interference peaks were found in any of the conditions.


**Detection and quantification limit:** The Limit of detection (LOD) and Limit of quantification (LOQ) were calculated using the following equation as per ICH guidelines from the prediction linearity graph.



**Figure 12:** Chromatogram represents unstressed sample.



**Figure 13:** Chromatogram represents an acid stressed sample.




**Figure 14:** Chromatogram represents the base stressed sample.

$$\text{LOD} = 3.3 \times \sigma / S$$


$$\text{and LOQ} = 10 \times \sigma / S,$$

Where  $\sigma$  is the standard deviation of y-intercept of the regression line and S is the slope of the calibration curve. Results are tabulated in Table 10 and respected chromatogram refers in Figure 21.







**Figure 15:** Chromatogram represents peroxide stressed sample.




**Figure 16:** Chromatogram represents photolytic stressed sample.



**Figure 17:** Chromatogram represents sunlight stressed sample.



**Figure 18:** Chromatogram represents thermal stressed sample.



**Figure 19:** Chromatogram represents humidity stressed sample.

Parameter	Specification	Results
Theoretical plates (N)	$\geq 2000$	FD: 4092
		Imp A: 4140
		Imp B: 4673
Tailing factor (T)	$\leq 1.5$	FD: 1.25
		Imp A: 1.16
		Imp B: 1.17
Resolution between Imp A and FD (R)	$\geq 1.5$	2.6
Resolution between FD and Imp C (R)	$\geq 1.5$	6.2

**Table 8:** System suitability parameters.

**Linearity:** The linearity was performed from a range of LOQ concentration to 150% of each related substance specification with respect to the sample concentration spiked into the sample containing 1 mg/mL and the correlation coefficient was found to be more than 0.999. Results are presented in Table 11 and the graph is shown in Figure 22.

**Repeatability:** The repeatability was performed by taking 6 determinations along with sample and 100% specified concentration of each impurity with respect to the sample concentration. Results are shown in Table 12.


**Intermediate precision:** The intermediate precision was performed

using different analyst on different days and using different instruments. Results are shown in Table 13.

**Reproducibility:** Reproducibility is performed as part of the test method transfer and will not be covered in this paper.

**Accuracy:** The accuracy was performed at LOQ, 50%, 100% and 150% of the specification of each impurity with respect to the sample concentration containing of 1 mg/mL of FD in three replicates. The results are shown in Table 14.

**Robustness:** Robustness was performed by varying the pH ( $\pm 0.1$ ),




**Figure 20:** Chromatogram of system suitability solution.

Name of the component	Relative retention time	Relative response factor
FD	1.00	1.00
Imp A	0.85	0.42
Imp B	0.69	0.92
Imp C	1.48	0.86

**Table 9:** Relative response factor determination.

Name of the component	% LOD	% LOQ
FD as unknown	0.005	0.015
Imp A	0.005	0.015
Imp B	0.005	0.015
Imp C	0.005	0.015

**Table 10:** % LOD and % LOQ.



**Figure 21:** Chromatogram represents at LOD concentration peaks of FD and its impurities.

Name of the component	Correlation coefficient	Slope	Intercept	Bias at 100%
FD as unknown	0.999	41982	169	0.01
Imp A	0.999	17875	-1620	0.8
Imp B	0.999	38648	1636	0.5
Imp C	0.999	35077	9065	3.1

**Table 11:** Linearity.

same column having different lot number, column temperature ( $\pm 5^\circ\text{C}$ ), wavelength ( $\pm 2\text{ nm}$ ) and flow rate ( $\pm 0.1\text{ mL/min}$ ). The results are shown in Table 15.


**Solution stability:** The impurities were stable up to 3 days in refrigerator ( $5^\circ\text{C}$ ) condition and up to 2 days at room temperature having the variations of not more than 10% of the initial value. The results are shown in Tables 16 and 17.

**Sample analysis:** Two different manufacturing drug substances and formulations were analyzed using this method to prove that the method

is suitable for the regular analysis. The peaks are well separated and no interference was observed, since the results were found to be within the specification; hence the method is suitable for routine analysis. The results are tabulated in Table 18.

## Conclusion

A Stability indicating method was developed and validated for the determination of FD impurities namely Imp A, B and C in solid dosage form and also in drug substance. The developed method was very robust, accurate, precise and linear across the concentration range;



**Figure 22:** Linearity graphs.

Name of the compound	Concentration in %						Average	SD	% RSD
	1	2	3	4	5	6			
Imp A	2.0602	2.0571	2.0590	2.0581	2.0576	2.0576	2.0583	0.001	0.1
Imp B	0.5475	0.5470	0.5484	0.5482	0.5479	0.5480	0.5478	0.001	0.1
Imp C	0.5285	0.5293	0.5262	0.5280	0.5278	0.5273	0.5279	0.001	0.2

**Table 12:** Results for method precision.

Name of the component	1	2	3	4	5	6	7	8	9	Average	SD	% RSD
	Analyst 1 Day 1 Instrument 1			Analyst 2 Day 2 Instrument 1			Analyst 1 Day 3 Instrument 2					
Imp A	2.060	2.057	2.059	2.061	2.058	2.061	2.070	2.054	2.067	2.061	0.005	0.2
Imp B	0.548	0.547	0.548	0.548	0.550	0.554	0.544	0.552	0.551	0.549	0.003	0.5
Imp C	0.529	0.529	0.526	0.527	0.529	0.527	0.525	0.522	0.525	0.527	0.002	0.4

**Table 13:** Precision data of proposed RP-HPLC method.

Name of the component	Mean recovery of LOQ	Mean recovery of 50%	Mean recovery of 100%	Mean recovery of 150%	SD	% RSD (precision)
Imp A	95.4	103.3	103.2	103.4	4.0	3.9
Imp B	96.0	105.7	103.7	102.4	4.2	4.1
Imp C	96.3	96.4	103.3	101.6	3.6	3.6

**Table 14:** Accuracy.

Actual condition	Changed condition	USP Theoretical Plates (N)	USP Tailing factor (T)	USP resolution between FD and	
				Imp A	Imp C
0.7 mL/min	0.6 mL/min	FD: 3934	FD: 1.32	2.7	6.3
		Imp A: 4050	Imp B: 1.21		
		Imp C: 4413	Imp C: 1.25		
	0.8 mL/min	FD: 3476	FD: 1.28	2.4	6.0
		Imp A: 3541	Imp A: 1.18		
		Imp C: 3965	Imp C: 1.19		
240 nm	238 nm	FD: 4192	FD: 1.26	2.6	6.2
		Imp A: 4150	Imp A: 1.14		
		Imp C: 4689	Imp C: 1.17		
	242 nm	FD: 4169	FD:	2.6	6.2
		Imp A: 4196	Imp A:		
		Imp C: 4598	Imp C:		
25°C	20°C	FD: 3566	FD: 1.32	2.7	6.3
		Imp A: 3656	Imp A: 1.21		
		Imp C: 4100	Imp C: 1.20		
	30°C	FD: 3985	FD: 1.32	2.5	6.1
		Imp A: 4001	Imp A: 1.21		
		Imp C: 4546	Imp C: 1.21		
5.0 pH	4.9 pH	FD: 3578	FD: 1.30	2.3	5.9
		Imp A: 3415	Imp A: 1.19		
		Imp C: 4021	Imp C: 1.18		
	5.1 pH	FD: 4126	FD: 1.31	2.6	6.4
		Imp A: 3945	Imp A: 1.20		
		Imp C: 4356	Imp C: 1.21		
Column	Column 1 Lot No: 5520-60	FD: 4092	FD: 1.25	2.6	6.2
		Imp A: 4140	Imp A: 1.16		
		Imp C: 4673	Imp C: 1.17		
	Column 2 Lot No: 5520-66	FD: 4510	FD: 1.19	2.6	6.2
		Imp A: 4351	Imp A: 1.06		
		Imp C: 4821	Imp C: 1.11		

**Table 15:** Robustness.

Data Evaluated	Initial	Day-1	Day-2	Day-3	% Variation
Imp A	2.061	2.131	2.216	2.297	11.5
Imp B	0.548	0.555	0.564	0.570	4.0
Imp C	0.529	0.533	0.539	0.543	2.6

**Table 16:** Solution stability at room temperature (25°C).

Data Evaluated	Initial	Day-1	Day-2	Day-3	% Variation
Imp A	2.061	2.065	2.071	2.078	0.8
Imp B	0.548	0.549	0.551	0.553	0.9
Imp C	0.529	0.530	0.530	0.533	0.8

**Table 17:** Solution stability at refrigerator (5°C).

Name of impurity	Drug substance-1	Drug substance-2	Formulation-1	Formulation-2	Specification (%)
Imp A (%)	0.00	0.01	0.02	0.39	<=2.0
Imp B (%)	0.03	0.04	0.05	0.25	<=0.5
Imp C (%)	0.24	0.22	0.25	0.18	<=0.5

**Table 18:** Sample analysis results.

hence this method can be used for the regular analysis and also for the stability testing of the samples.

#### Acknowledgement

The authors express their gratitude towards the department of analytical research and development, Ashland India Private Limited, Hyderabad, Telangana, India for the support in terms of research facilities and samples.

#### References

- Annapurna, MM, Kumar BSP, Goutam SVS (2013) Stability-indicating RP-HPLC method for the determination of felodipine (a calcium channel blocker) in tablets. Indo American Journal of Pharmaceutical Research 3: 9277-9285.
- Williams M (2013) The Merck index: an encyclopedia of chemicals, drugs, and biologicals. O'Neil MJ 15<sup>th</sup> (Edn), RSC Publishing 74: 339

3. Nyborg NCB, Mulvany MJ (1984) Effect of felodipine, a new dihydropyridine vasodilator, on contractile responses to potassium, noradrenaline, and calcium in mesenteric resistance vessels of the rat. J Cardiovasc Pharmacol 6: 499-505.
4. Hu L, Hu Q, Na G (2013) A validated, stability-indicating HPLC method for the determination of Felodipine and its related substances. International Journal of Pharmaceutical Sciences and Research 4:3369-3374.
5. Walash MI, Belal FF, El-Enany NM, El-Maghrabey MH (2011) Synchronous fluorescence spectrofluorimetric method for the simultaneous determination of metoprolol and felodipine in combined pharmaceutical preparation. Chem Cent J 5: 70.
6. Bazzo GC, Caetano DB, Boch ML, Mosca M, Branco LC, et al. (2012) Enhancement of felodipine dissolution rate through its incorporation into Eudragit® E-PHB polymeric microparticles: *in vitro* characterization and investigation of absorption in rats. J Pharm Sci 101: 1518-1523.
7. Singh S, Bakshi M (2000) Stress test to determine inherent stability of drugs. Pharmaceutical technology 4: 1-14.
8. Szepesi G, Gazdag M, Mihalyfi K (1991) Selection of high-performance liquid chromatographic methods in pharmaceutical analysis: III. Method validation. J Chromatogr 464: 265-278.
9. (1996) ICH, "Validation of Analytical Procedures: Methodology," Proceeding of the International Conference on Harmonization, Geneva.

**Citation:** Vadlamudi MK, Dhanaraj S (2016) Stability Indicating Method for the Determination of Related Substances in Felodipine Solid Dosage Form and in the Drug Substance by RP-HPLC. J Bioequiv Availab 8: 153-166. doi:[10.4172/jbb.1000287](https://doi.org/10.4172/jbb.1000287)

### OMICS International: Open Access Publication Benefits & Features

#### Unique features:

- Increased global visibility of articles through worldwide distribution and indexing
- Showcasing recent research output in a timely and updated manner
- Special issues on the current trends of scientific research

#### Special features:

- 700+ Open Access Journals
- 50,000+ editorial team
- Rapid peer review process
- Quality and quick editorial, review and publication processing
- Indexing at major indexing services
- Sharing Option: Social Networking Enabled for better prominence and citations
- Authors, Reviewers and Editors rewarded with online Scientific Credits
- Best discounts for your subsequent articles

Submit your manuscript at: <http://www.editorialmanager.com/jbiobio>